Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

Registration Number
NCT03019640
Lead Sponsor
M.D. Anderson Cancer Center
Brief Summary

This phase II trial studies the side effects of cord blood-derived expanded allogeneic natural killer cells (umbilical cord blood natural killer \[NK\] cells), rituximab, high-dose chemotherapy, and stem cell transplant in treating patients with B-cell non-Hodgkin's lymphoma that has come back (recurrent) or that does not respond to treatment (refractory). I...

Detailed Description

PRIMARY OBJECTIVE:

I. To establish the safety of this treatment by determining its treatment-related mortality (TRM) within 30 days.

SECONDARY OBJECTIVES:
...

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
22
Inclusion Criteria
  • Patients with B-cell lymphoma who are candidates to autologous stem-cell transplantation:

    • Primary refractory or relapsed diffuse large B-cell lymphoma in response to salvage treatment
    • Primary refractory or relapsed follicular lymphoma or other indolent B-cell histology in response to salvage treatment
    • Chemosensitive mantle-cell lymphoma in first or later line of treatment
  • Estimated serum creatinine clearance >= 60 ml/min and a normal serum creatinine for age

  • Serum glutamic-oxaloacetic transaminase (SGOT) and/or serum glutamate pyruvate transaminase (SGPT) =< 3 x upper limit of normal (ULN)

  • Total bilirubin and alkaline phosphatase (ALP) =< 2 x ULN or =< 3 x ULN for Gilbert's disease

  • Forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and diffusion lung capacity (DLCO) (corrected for hemoglobin [Hgb]) >= 50% of the predicted value

  • Left ventricular ejection fraction >= 40%. No uncontrolled arrhythmias or symptomatic cardiac disease

  • Performance status < 2 (Eastern Cooperative Oncology Group [ECOG])

  • Negative beta human chorionic gonadotropin (HCG) in woman with child-bearing potential

Read More
Exclusion Criteria
  • Primary central nervous system (CNS) lymphoma
  • Grade >= 3 non-hematologic toxicity from prior therapy that has not resolved to =< grade (G) 1
  • Prior whole brain irradiation
  • Active hepatitis B, either active carrier (hepatitis B surface antigen positive [HBsAg +]) or viremic (hepatitis B virus [HBV] deoxyribonucleic acid [DNA] >= 10,000 copies/mL, or >= 2,000 IU/mL)
  • Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serology
  • Active infection requiring parenteral antibiotics
  • Human immunodeficiency virus (HIV) infection
  • Radiation therapy in the month prior to enroll
  • Breastfeeding females
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Treatment (chemotherapy, NK infusion, stem cell transplant)Cord Blood-derived Expanded Allogeneic Natural Killer CellsSee Detailed Description.
Treatment (chemotherapy, NK infusion, stem cell transplant)Autologous Hematopoietic Stem Cell TransplantationSee Detailed Description.
Treatment (chemotherapy, NK infusion, stem cell transplant)FilgrastimSee Detailed Description.
Treatment (chemotherapy, NK infusion, stem cell transplant)RituximabSee Detailed Description.
Treatment (chemotherapy, NK infusion, stem cell transplant)LenalidomideSee Detailed Description.
Treatment (chemotherapy, NK infusion, stem cell transplant)CarmustineSee Detailed Description.
Treatment (chemotherapy, NK infusion, stem cell transplant)CytarabineSee Detailed Description.
Treatment (chemotherapy, NK infusion, stem cell transplant)EtoposideSee Detailed Description.
Treatment (chemotherapy, NK infusion, stem cell transplant)MelphalanSee Detailed Description.
Primary Outcome Measures
NameTimeMethod
Treatment-related Mortality Within 30 Days (TRM30)Up to 30 days

Participants that had Treatment-related mortality within 30 days.

Secondary Outcome Measures
NameTimeMethod
Number of Participants Who SurvivedFrom the time of transplant, assessed up to day 180

Number of Participants Who Survived at day 180.

Trial Locations

Locations (1)

M D Anderson Cancer Center

🇺🇸

Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath